A vaccine given during pregnancy is dramatically reducing hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, offered to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the primary reasons of hospital admission in babies under one year old, with more than 20,000 serious cases documented annually across the UK.
How the immunisation protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns during their first few months of life. The virus can range from causing mild, cold-like symptoms to triggering severe chest infections that cause babies to struggle to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the distressing nature of serious RSV infections: “In babies with bad infections you can see their chest and lungs working hard, as they attempt to draw enough oxygen in. This is very, very frightening as a parent, frightening with good reason.”
The pregnancy vaccine operates by stimulating the mother’s immune system to generate protective antibodies, which are then passed to the developing baby through the placenta. This maternal immunity provides newborns with instant defence from the point of delivery, exactly when they are most vulnerable to RSV. The latest research shows that protection reaches nearly 85 per cent when the vaccine is given at least four weeks before delivery. Even shorter intervals between vaccination and birth can still deliver meaningful protection, with evidence suggesting that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to have the vaccine at the recommended time, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when vaccinated four weeks before birth
- Maternal antibodies passed through placenta safeguard newborns from birth
- Coverage achievable with 2-week gap before early delivery
- Vaccination during the third trimester still offers meaningful protection for infants
Persuasive evidence from the latest research
The efficacy of the pregnancy RSV vaccine has been established through a thorough investigation conducted across England, reviewing data from nearly 300,000 babies born between September 2024 and March 2025. This accounts for approximately nine out of ten of all births during that half-year window, providing strong and reliable data of the vaccine’s actual performance. The study’s findings have been supported by the UK Health Security Agency as showing robust protection for newborns during their earliest and most vulnerable period. The scope of this study gives healthcare professionals and prospective parents with assurance in the vaccine’s proven efficacy across diverse populations and circumstances.
The results reveal a notable picture of the vaccine’s protective power. More than 4,500 babies were treated in hospital with RSV during the study period, with the great majority being infants whose mothers had not been given the vaccination. This marked difference highlights the vaccine’s vital importance in protecting against serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a substantial public health milestone, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms linked to severe RSV infection. These findings support the importance of the vaccination programme established in the UK in 2024.
Study design and parameters
The research reviewed birth and hospitalisation records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to both vaccinated and unvaccinated mothers, researchers were able to identify direct comparisons of RSV infection levels and hospital admissions. The sizeable sample and thorough nature of the data collection ensured that findings were statistically significant and representative of the broader population, rather than isolated cases or small subgroups.
The study specifically recorded hospital admissions for RSV among infants born to mothers who had been given the vaccine at different timepoints before delivery. This allowed researchers to identify the least amount of time between vaccination and birth for maximum protection, as well as to determine whether protection stayed significant with reduced timeperiods. The methodology measured actual clinical results rather than controlled laboratory conditions, providing real-world data of how the vaccine functions when delivered across different clinical contexts and patient circumstances throughout the final three months of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Learning about RSV and its risks
Respiratory syncytial virus, typically known as RSV, is among the primary causes of hospital admission in infants under one year of age across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing enormous strain on paediatric wards and neonatal units during busier periods.
The infection produces inflammation deep within the lungs and airways, making it dangerously difficult for affected infants to breathe and feed effectively. Parents commonly see their babies struggling visibly, their chests rising whilst they attempt to draw sufficient oxygen into their damaged lungs. Whilst most infants improve through clinical support, a modest yet notable proportion perish from RSV complications annually, making immunisation programmes a critical public health objective for safeguarding the youngest and most at-risk individuals in the population.
- RSV triggers lung inflammation, leading to serious respiratory problems in babies
- Half of all infants acquire the virus in their first few months of life
- Symptoms vary between minor cold-like symptoms to serious chest infections that threaten life requiring hospitalisation
- Over 20,000 UK babies need serious hospital treatment for RSV annually
- Few babies succumb to RSV related complications each year in the UK
Adoption rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have highlighted the significance of pregnant women receiving their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that the timing is essential for guaranteeing newborns receive the maximum immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers nearly 85% protection, experts encourage women to receive their vaccine as soon as feasible from 28 weeks of pregnancy onwards to increase the antibodies passed to their babies through the placenta.
The guidance from public health bodies stays clear: pregnant women should prioritise getting vaccinated during their final three months, even if circumstances mean they cannot get vaccinated at the optimal time. Dr Watson has provided reassurance to pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the practical demands of pregnancy whilst maintaining strong safeguarding for at-risk infants during their earliest and most vulnerable period when RSV poses the greatest risk of severe infection.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have differed across various areas and NHS trusts. Certain regions have achieved greater immunisation rates among qualifying expectant mothers, whilst others continue working to increase awareness and access to the jab. These geographical variations reflect differences across healthcare infrastructure, engagement approaches, and local engagement efforts, though the national data shows robust and reliable protection regardless of geographical location.
- NHS trusts launching multiple messaging strategies to reach women during pregnancy
- Geographic variations in vaccination coverage levels throughout England demand focused enhancement
- Regional health providers adapting programmes to meet community needs and circumstances
Practical implications and parental perspectives
The vaccine’s outstanding effectiveness provides tangible benefits for families across the United Kingdom. With over 20,000 babies admitted to hospital annually due to RSV prior to the launch of this protective measure, the 80% reduction in admissions equates to thousands of infants spared from severe infection. Parents no longer face the distressing scenario of watching their newborns gasping for air or difficulty feeding, symptoms that characterise severe RSV infections. The vaccine has markedly changed the picture of neonatal respiratory health, giving expectant mothers a preventative option to safeguard their youngest infants during those vital initial period.
For families like that of Malachi, whose serious RSV infection resulted in devastating brain damage, the vaccine’s availability carries profound emotional significance. His mother’s advocacy for the jab underscores the life-altering consequences that vaccine-preventable disease can inflict on young children and their families. Whilst Malachi’s experience comes before the vaccine programme, his story resonates powerfully with parents now offered protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now largely avoidable has given considerable reassurance to expectant mothers navigating their late pregnancy, converting what was once an inevitable seasonal threat into a controllable health concern.